| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-03-20 | TC-5214 | major depressive disorder (MDD) | 3 | AstraZeneca (UK) | CNS diseases - Mental diseases |
| 2012-03-20 | JX594/TG6006 (Pexa-Vec) | metastatic colorectal cancer | 1-2 | Transgene (France) Jennerex (USA) | Cancer Oncology |
| 2012-03-20 | XEN-D0103 | treatment and prevention of atrial fibrillation |
1 | Xention (UK) | Cardiovascular diseases |
| 2012-03-16 | cystic fibrosis (CF) gene included in a plasmid and administered via a nebulizer | cystic fibrosis |
2 | Oxford University (UK) Imperial College London (UK) The Edinburgh University (UK) | Rare diseases - Genetic diseases |
| 2012-03-14 | HCV vaccine | hepatitis C | 1-2 | Okairos (Switzerland) | Infectious diseases |
| 2012-03-13 | EN41-FPA2 HIV Vaccine | HIV-/Aids | 1 | PX’Therapeutics (France) | Infectious diseases |
| 2012-03-13 | simeprevir (TMC435) | hepatitis C genotype-1 infected patients who were null or partial responders to prior PegINF/RBV therapy | 3 | Tibotec Pharmaceuticals-J&J (Ireland - USA) Medivir (Sweden) | Infectious diseases |
| 2012-03-13 | simeprevir (TMC435) | Hepatitis C genotype-4 infected patients | 3 | Tibotec Pharmaceuticals-J&J (Ireland - USA) Medivir (Sweden) | Infectious diseases |
| 2012-03-13 | BOL-303259-X | open-angle glaucoma ocular hypertension |
2b | NicOx (France) Bausch&Lomb (USA) | Ophtalmological diseases |
| 2012-03-12 | oral alitretinoin | severe chronic hand eczema | 3 | Basilea Pharmaceutica (Switzerland) | Dermatological diseases |
| 2012-03-08 | CYT107 (Recombinant human interleukin-7) | treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART). | 2 | Cytheris (France) | Infectious diseases |
| 2012-03-08 | ToleroMune® ragweed allergy vaccine | ragweed allergy |
2 | Circassia (UK) | Allergic diseases - Immune diseases |
| 2012-03-07 | Signifor® (pasireotide) | Cushing's disease | 3 | Novartis (Switzerland) | Rare diseases |
| 2012-03-06 | OGA (O-linked N-acetylglucosaminidase) inhibitor programme | tauopathies including Alzheimer’s disease | in vivo non clinical studies | Summit (UK) | Neurodegenerative diseases |
| 2012-03-06 | Kappaproct® | chronic active ulcerative colitis | 3 | InDex Pharmaceuticals (Sweden) | Inflammatory diseases - Autoimmune diseases |
| 2012-03-06 | ARUP Septin9 test | colorectal cancer | Epigenomics (Germany-USA) | Cancer Oncology | |
| 2012-03-06 | Vyvanse® (lisdexamfetamine dimesylate) | Attention-Deficit Hyperactivity Disorder (ADHD) |
4 | Shire (UK-USA) | CNS diseases - Mental diseases |
| 2012-03-06 | Cinryze® in combination with Halozyme\'s Enhanze™ technology | hereditary angioedema | 2 | Viropharma (USA) Halozyme Therapeutics (USA) | Rare diseases - Genetic diseases |
| 2012-03-05 | Ragweed AIT | ragweed allergy |
3 | Merck&Co (USA) ALK (Denmark) | Allergic diseases - Immune diseases |
| 2012-03-05 | Dymista® MP29-02 | seasonal allergic rhinitis | Meda (Sweden) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
